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Growth-factor reduced Matrigel source 
influences stem cell derived brain microvascular 
endothelial cell barrier properties
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Abstract 
Background: Patient-derived induced pluripotent stem cells (iPSCs) are an innovative source as an in vitro model for 
neurological diseases. Recent studies have demonstrated the differentiation of brain microvascular endothelial cells 
(BMECs) from various stem cell sources, including iPSC lines. However, the impact of the culturing conditions used to 
maintain such stem cell pluripotency on their ability to differentiate into BMECs remains undocumented. In this study, 
we investigated the effect of different sources of Matrigel and stem cell maintenance medium on BMEC differentia-
tion efficiency.
Methods: The IMR90-c4 iPSC line was maintained on mTeSR1 or in essential-8 (E-8) medium on growth factor-
reduced (GFR) Matrigel from three different manufacturers. Cells were differentiated into BMECs following published 
protocols. The phenotype of BMEC monolayers was assessed by immunocytochemistry. Barrier function was assessed 
by transendothelial electrical resistance (TEER) and permeability to sodium fluorescein, whereas the presence of drug 
efflux pumps was assessed by uptake assay using fluorescent substrates.
Results: Stem cell maintenance medium had little effect on the yield and barrier phenotype of IMR90-derived 
BMECs. The source of GFR-Matrigel used for the differentiation process significantly impacted the ability of IMR90-
derived BMECs to form tight monolayers, as measured by TEER and fluorescein permeability. However, the Matrigel 
source had minimal effect on BMEC phenotype and drug efflux pump activity.
Conclusion: This study supports the ability to differentiate BMECs from iPSCs grown in mTeSR1 or E-8 medium and 
also suggests that the origin of GFR-Matrigel has a marked inpact on BMEC barrier properties.
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Background
The blood–brain barrier (BBB), or neurovascular unit, 
provides a stable and defined microenvironment for the 
central nervous system (CNS). Among the different types 
of cells forming the BBB, brain microvascular endothe-
lial cells (BMECs) provide both a physical and chemical 
barrier, tightly regulating the diffusion of water, ions and 
lipophilic compounds into the CNS [1–4].
In vitro models of the BBB are valuable tools for drug 
discovery research as they provide an insight into the 
diffusion profile of existing and prospective drug candi-
dates targeting the CNS [2, 5]. However, the current use 
of in vitro models of the human BBB based on primary 
cultures and immortalized cell lines remains hampered 
by their limited barrier tightness [6].
Recently, several studies have documented success in 
differentiating BMECs from stem cell sources, includ-
ing human pluripotent stem cells such as embryonic 
stem cells (hESCs), hematopoietic stem cells (HSCs) 
and induced pluripotent stem cells (iPSCs) [7–10]. 
Such stem cell-derived BMECs share similarities with 
established models including the expression of tight 
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junction proteins, the formation of a tight monolayer 
and the expression of functional drug transporters. Sev-
eral parameters have been described as important for 
the generation of human pluripotent stem cell-derived 
BMECs in order to achieve barrier tightness suitable for 
drug permeability screening. These include cell density 
[11], the addition of retinoic acid [7], and co-culture with 
astrocytes and neurons [7, 8]. However, the ability to 
translate the differentiation protocol for patient-derived 
iPSCs may be hampered by variations in stem cell main-
tenance protocols. For instance, human pluripotent stem 
cells (hPSCs) grown and maintained in a feeder-free sys-
tem are routinely grown on growth factor reduced (GFR) 
Matrigel- or vitronectin-N (VTN)-coated tissue culture 
plastic surfaces [12, 13], supplemented with mTeSR1 
or essential 8 medium (E8) [12, 13]. GFR Matrigel con-
stitutes a complex extracellular matrix (ECM) mixture 
secreted by Engelbreth–Holm–Swarm mouse sarcoma 
cells with an approximate composition of 60 % laminin, 
30 % collagen IV and 8 % entactin as well as other unde-
fined ECM components [14]. Because of its complexity, 
Matrigel remains undefined and may constitute a source 
of variability that can impact hPSC-derived BMEC dif-
ferentiation efficacy [15]. However, the effect of other 
culturing conditions (ECMs and media) on the outcome 
of hPSC-derived BMEC differentiation remains undocu-
mented. In this study, we investigated the effects of dif-
ferent ECMs and stem cell maintenance medium on 
IMR90-c4 human iPSC line, a cell line with a highly-doc-
umented BMEC differentiation profile.
Methods
The undifferentiated IMR90 (IMR90-c4) iPSC line [13] 
(WiCell, Madison, WI, USA) was maintained in mTeSR 
(mTeSR1, Stem Cell Technologies, Vancouver BC, 
Canada) or in essential-8 medium (E-8, ThermoFisher, 
Waltham, MA, USA) on hESC-qualified GFR-Matrigel 
(C-Matrigel, Corning, Corning, NY, USA) [13].
Undifferentiated IMR90-c4 iPSC colonies were rou-
tinely maintained on 6-well tissue culture plates (Corn-
ing) coated with C-Matrigel in presence of mTeSR1 or 
E-8 medium. Prior to differentiation, cells were dissoci-
ated as single cells using Accutase cell detachment solu-
tion (Corning) and seeded at a seeding density of 8 × 103 
cells/cm2 (B-Matrigel) or 20  ×  103 cells/cm2 on tissue 
culture plates (Corning). Plates were coated with one of 
the following hESC-qualified GFR-Matrigels at a con-
centration 8.3  µg/cm2 for B-Matrigel, (BD Biosciences, 
Fairleigh, NJ, USA) and T-Matrigel, (Trevigen, Gaithers-
burg, MD, USA) or at a dilution indicated by the man-
ufacturer for C-Matrigel; L-Matrigel, and Vitronectin 
(ThermoFisher, Waltham, MA, USA). This study was 
conducted with at least two distinct ECM batches serial 
numbers. After 5  days of culture, IMR90 iPSCs became 
differentiated into BMECs as previously reported [7, 11]. 
In brief, cells were maintained in unconditioned medium 
(UM; DMEM/F12 with 15  mM HEPES supplemented 
with 20 % KO serum replacement, 1 % MEM non-essen-
tial aminoacids, and 0.5  % Glutamax I, ThermoFisher) 
and 0.1 mM β-mercaptoethanol (Sigma-Aldrich, St Louis, 
MO, USA) for six consecutive days, with the medium 
replaced daily. After 6  days of differentiation, IMR90-
derived BMECs were further matured in EC differentia-
tion medium (EC serum free medium (ThermoFisher), 
supplemented with 1  % platelet-poor derived plasma 
serum (ThermoFisher), 20  µg/mL human basic fibro-
blast growth factor (R&D Systems) and 10  µM all-trans 
retinoic acid (Sigma-Aldrich) for 2 days. After 8 days of 
differentiation, cells were enzymatically dissociated and 
seeded at a density of 106 cells/cm2 on 12-well transwell 
polyester cell culture inserts (0.4  µm pore size) coated 
with collagen from human placenta (Sigma-Aldrich) and 
fibronectin from bovine plasma (Sigma-Aldrich) at con-
centrations of 80 and 20  µg/cm2 respectively as previ-
ously published [7, 11]. After 24 h (day 9), BMECs were 
maintained in EC differentiation medium containing 
only 1  % platelet-poor plasma-derived serum. On day 
10, 48  h after seeding, transendothelial electrical resist-
ance (TEER) was assessed using an EVOM STX2 chop-
stick electrode (World Precision Instruments, Sarasota, 
FL, USA) and by measuring permeability (Pe) to sodium 
fluorescein solution (1 μg/mL, Sigma-Aldrich) using the 
clearance slope method as previously reported [7, 11, 16].
The immunostaining procedure on fixed cells was 
identical to that previously published [7, 11]. Cells were 
visualized on an Olympus IX81 inverted epifluorescence 
microscope. Photomicrographs were acquired using 
Slidebook 4.5 (Intelligent Imaging Innovation, Denver, 
CO, USA) and processed with ImageJ (NIH, Bethesda, 
MD, USA).
Drug efflux pump activity was assessed using the same 
accumulation assays as previously reported [7, 11]. In 
brief, BMECs monolayers were incubated in presence 
of 10  µM Rhodamine 123 and 10  µM BODIPY-FL pra-
zosin (Sigma-Aldrich), 5  µM doxorubicin or 10  µM 
CM-DCFDA for 1  h at 37  °C. For experiments involv-
ing inhibitors, cells were pre-incubated in presence of 
cyclosporine A (CsA), 5  µM, Ko143, 1  µM, or MK571, 
10  µM (Sigma-Aldrich) for 1  h prior to the experiment 
and maintained during the whole procedure. Cells were 
washed with ice-cold PBS and lysed using RIPA extrac-
tion buffer (ThermoFisher). The fluorescence of the cell 
extract was assessed using a fluorescent plate reader 
(SynergyMX2, BioTek, Burlington, VT, USA). Raw fluo-
rescence units (RFU) were adjusted to the cell extract 
protein concentration (as determined by BCA assay) to 
Page 3 of 7Patel and Alahmad  Fluids Barriers CNS  (2016) 13:6 
determine the drug uptake (expressed as RFU/µg pro-
tein). The drug uptake in untreated (without inhibitors) 
monolayers was arbitrarily set at 100  % and identified 
as control. The drug uptake in treated monolayers (with 
pharmacological inhibitors) was normalized to their 
respective controls, as previously published [7, 11].
Data are expressed as mean ± SD from a minimum of 
six experiments (two distinct ECM batches, three distinct 
differentiation passages for each batch. For each pas-
sage, experiments were done with two technical dupli-
cates). Statistical analysis was performed using one-way 
ANOVA using Prism 6.0 statistical package (Graphpad 
Software, La Jolla, CA, USA).
Results
Experiments using mTeSR medium
We first investigated the impact of different Matrigel 
sources on undifferentiated IMR90 stem cell growth 
and maintenance in mTeSR medium at a seeding den-
sity of 20 × 103 cells/cm2 (Fig. 1a). In our hands, IMR90 
iPSC colonies grown on B-Matrigel, L-Matrigel   and 
T-Matrigel showed similar doubling times (27.28, 26.69 
and 24.49 h respectively), however IMR90 cells grown on 
C-Matrigel showed a much slower growth rate, with an 
average doubling time of 42.30 h. We found that cultur-
ing IMR90 iPSCs on C-Matrigel and T-Matrigel with a 
starting seeding cell density of 8 × 103 cells/cm2 as previ-
ously reported [11], failed to achieve a complete differen-
tiation and we noted a significant cell loss after 3–4 days 
of growth in unconditioned medium (UM, data not 
shown). A satisfactory differentiation was only achieved 
when we set our seeding cell density at 20 ×  103  cells/
cm2 and allowed our colonies to grow for 5  days. At 
this seeding density, the yield (calculated as the num-
ber of cells harvested at day 8 of differentiation versus 
the initial seeding density at day 0) was approximately 
26.92 ± 4.69-fold increase in B-Matrigel group, but was 
lower in C- and T-Matrigel, with increases of 6.30 ± 1.32 
and 4.03 ± 1.32-fold, respectively (Fig. 1b). Upon purifi-
cation, we noted a homogenous BMEC cell monolayer in 
all three groups, as these cells expressed markers repre-
sentative of the vascular endothelial lineage (PECAM-1, 
VE-cadherin), and also the expression of BBB markers 
(GLUT1, claudin-5, occludin), consistent with the exist-
ing literature (Fig. 1c) [7, 8, 11]. Taken together, our data 
suggest that Matrigel from different sources may affect 
the outcome in terms of BMEC differentiation and yield.
Next, we assessed the barrier properties of such 
monolayers in monocultures by measuring both 
transendothelial electrical resistance (TEER) and para-
cellular permeability to sodium fluorescein (NaF). On 
B-Matrigel, IMR90 showed TEER (Fig.  2a) values of 
1332 ± 558 Ω cm2. In contrast, BMECs differentiated on 
C-Matrigel displayed a much lower TEER and the average 
electrical resistance measured was 424.3 ± 205.1 Ω cm2. 
Finally, on T-Matrigel we noted showed TEER values of 
1439 ± 281.4 Ω cm2. Using a different technique to con-
firm such differences in the barrier function, we meas-
ured changes in paracellular permeability using sodium 
fluorescein (NaF) as a paracellular marker (Fig.  2b). 
In our hands, we noted permeability (Pe) values of 
0.44  ×  10−4 cm/min on monolayers differentiated on 
B-Matrigel. Cells differentiated on C-Matrigel showed a 
tenfold higher permeability, with an average Pe value of 
4.20 × 10−4 cm/min, whereas cells grown on T-Matrigel 
had a Pe value of 1.57 × 10−4 cm/min.
In addition, we investigated the expression (Fig. 2c) and 
activity (Fig.  3) of P-glycoprotein (P-gp), breast cancer 
resistant protein (BCRP) and multidrug resistant protein 
(MRP) by immunocytochemistry and by drug accumu-
lation assay, respectively. In our hands, all groups had 
Fig. 1 Effects of Matrigel origin on IMR90 iPS cell growth and BMEC 
differentiation using mTeSR medium. a Undifferentiated IMR90 
cells maintained in mTeSR were dissociated as single cells seeded 
on Matrigel from BD Biosciences (B-Matrigel, blue), from Corning 
(C-Matrigel, orange), from ThermoFisher (L-Matrigel, red) or from 
Trevigen (T-Matrigel, purple) at 20 × 103 cells/cm2. After 24, 48 and 
72 h following cell seeding, IMR90 iPSC colonies were dissociated 
and counted using a cell hemocytometer and Trypan blue exclu-
sion assay. b BMEC yield after 8 days of differentiation obtained by 
calculating the ratio of cell density at 8 days of differentiation versus 
the initial cell density seeded at day 0, ** denotes P < 0.01 in compari-
son to B-Matrigel. c Representative immunostained micrographs of 
PECAM-1, VE-cadherin, Glut-1 Claudin 5 and Occludin expression in 
purified BMEC monolayers 48 h post-purification. Note the formation 
of a monolayer as marked by defined tight junction complexes in 
one focal plane and the absence of junctional cellular overlap. Scale 
bar = 20 µm
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positive expression for P-gp, BCRP and MRP1 (Fig. 2c); all 
three proteins were detected in our monolayers and this 
was consistent with the existing literature [7, 8, 11]. We 
did not notice any dramatic differences in immunoreac-
tivity between the three groups. Thus we consider there 
are similar protein expression levels in all groups. To dem-
onstrate that Matrigel had little effect on drug efflux pump 
activity, we assessed changes in efflux activity by measur-
ing, in the presence or absence of inhibitors, uptake of 
rhodamine 123, FL-BODIPY prazosin, and CM-DCFDA 
as these fluorescent dyes are known substrates for P-gp 
[17], BCRP [18–20] and MRPs [21], respectively (Fig. 3). 
The net uptake (the difference in fluorescence between 
untreated group designated 100  %, and inhibitor-treated 
group), was not significantly different for P-gp-mediated 
efflux between the groups (Fig.  3a, upper panel). How-
ever, we noted a 1.7 fold increase in uptake of rhodamine 
123 following inhibition with 5 µM CsA: this increase was 
consistent with the previous literature [7, 8, 11]. A similar 
outcome was observed in the net uptake of FL-BODIPY 
prazosin following inhibition with Ko143 (Fig. 3a, middle 
panel). However, we noted a slight but significant differ-
ence in net uptake of CM-DCFDA in that cells grown on 
B-Matrigel showed a 2.3 fold-increase in uptake in pres-
ence of MK571 compared to control, whereas cells grown 
on T-Matrigel showed only a 1.6 fold-increase in uptake 
compared to control (Fig. 3a, lower panel). Because such 
substrates are not exclusive to their efflux pumps and may 
interact with other efflux pumps, we further confirmed 
the presence of efflux pump activity using doxorubicin, a 
substrate for all three pumps (Fig. 3b). With the exception 
of a twofold increase in doxorubicin net uptake following 
CsA treatment in the T-Matrigel group, we did not notice 
any significant differences in the net uptake between 
the different Matrigel groups. We noted an increase of 
1.3 to 1.4-fold compared to control, which is consist-
ent with previous literature [7]. In conclusion, the source 
of Matrigel influenced the barrier outcome in IMR90-
derived BMECs in terms of barrier tightness but not in 
terms of drug efflux-mediated transport.
Experiments using essential‑8 medium
Because GFR-Matrigel from different sources dis-
played variable outcomes on IMR90 differentiation into 
BMECs, and also that the production of B-Matrigel has 
Fig. 2 Matrigel origin impacts BMECs barrier properties. a, b TEER 
and sodium fluorescein permeabilities in IMR90-derived BMECs dif-
ferentiated on B-, C- or T-Matrigel. Note the degraded barrier function 
of cells grown on C-Matrigel compared to the two other groups. * 
and ** denotes P < 0.05 and P < 0.01 in comparison to B-Matrigel. c 
Representative immunostained micrographs of P-gp, BCRP and MRP1 
expression in purified BMECs monolayers. Scale bar = 40 µm
Fig. 3 Matrigel origin has a minor impact on BMECs drug efflux 
activity. a Drug uptake of rhodamine 123, BODIPY FL-prazosin and 
CM-DCFDA in presence of 5 μM cyclosporine A (CsA, P-gp inhibitor), 
1 μM Ko143 (BCRP inhibitor) or 10 μM MK571 (pan-MRP inhibitor), 
respectively. Fluorescence values in controls (no inhibitor) were 
arbitrarily set to 100 %, * and ** denote P < 0.05 and P < 0.01 in com-
parison to B-Matrigel. b Doxorubicin accumulation profile in presence 
of CsA, Ko143 or MK571. Doxorubicin net uptake was calculated as 
previously described
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been discontinued, we investigated alternative culturing 
conditions that can circumvent these issues. In particu-
lar, we investigated the possibility to change the BMEC 
differentiation protocol using defined conditions with, 
E-8 medium and two additional ECMs, vitronectin and 
L-Matrigel (Fig. 4). Undifferentiated IMR90 iPSCs grown 
on C-Matrigel in presence of E-8 medium (Fig. 4a, orange 
line), showed a doubling time similar to mTeSR (26.72 
and 27.28 h respectively), as well as cells grown on Gel-
trex [L-Matrigel (red line), 20.31  h] and Vitronectin-N 
[Vitronectin (green line), 29.69 h]. However, cells grown 
on T-Matrigel (purple line) in combination with E-8 
medium displayed a much reduced growth rate com-
pared to mTeSR with an average doubling time of 41.05 h. 
By maintaining the same seeding density as previously 
mentioned, we obtained after 8  days of differentiation 
an average BMEC yield (Fig.  4b) of 15.45  ±  9.08 and 
14.66 ±  8.78-fold increase in cells grown in C-Matrigel 
and T-Matrigel respectively. Surprisingly, cells grown on 
L-Matrigel or on Vitronectin were incapable of reach-
ing a yield that was higher than twofold. Next we com-
pared the average barrier function of these monolayers 
by measuring changes in TEER and permeability (Fig. 4c, 
d). Maintenance of IMR90 iPSCs in E-8 did not interfere 
with the BMEC barrier tightness, as we noted TEER val-
ues (305.4 ± 85.09 and 1254 ± 523.7 Ω cm2) and perme-
ability (3.66 ± 1.20 and 0.54 ± 0.13 × 10−4 cm/min) for 
C and T-Matrigels, similar to those reported in IMR90 
iPSCs maintained in mTeSR media. However, cells differ-
entiated on L-Matrigel and Vitronectin showed poor bar-
rier properties, as noted by lower TEER (169.0 ±  32.86 
and 23.75  ±  16.99  Ω  cm2) and higher permeabilities 
(5.76  ±  1.05 and 9.50  ±  2.90  ×  10−4  cm/min). Finally, 
we investigated changes in drug efflux activity by meas-
uring changes in rhodamine 123, FL-BODIPY prazosin 
and CM-DCFDA uptake in cells grown on both C- and 
T-Matrigel (Fig.  5). We observed similar trends to cells 
maintained in mTeSR prior to differentiation (Fig.  5a), 
although the net uptake values for each pumps were 
Fig. 4 Essential-8 medium does not impact BMECs differentiation. 
a IMR90 iPSC growth curve on C-Matrigel (orange), L-Matrigel (red), 
T-Matrigel (purple) or vitronectin (green)-coated surfaces. IMR90 iPSCs 
were seeded as single cells at day 0 at a density of 20 × 103 cells/cm2 
on the different types of matrices and maintained in E-8 medium. 
At each timepoint (day), IMR90 iPSC colonies were dissociated as 
single cells using Accutase and counted with a cell hemocytometer 
using 0.4 % Trypan blue as an exclusion dye. b Cell yield at day 8 of 
differentiation. Cell yield was determined by dividing average density 
at day 8 of differentiation by the initial cell seeding density at day 
0. c, d TEER and sodium fluorescein permeability values on purified 
iPSC-derived BMECs monolayers 48 h after purification. Note the poor 
barrier properties in cells differentiated on Geltrex (L-Matrigel) or on 
vitronectin-N (vitronectin), * and ** denote P < 0.05 and P < 0.01 in 
comparison to C-Matrigel
Fig. 5 Essential-8 medium. a Drug uptake profile of rhodamine 
123, BODIPY-prazosin and CM-DCFDA in presence of CsA, Ko143 
or MK571. Drug uptakes of the same efflux substrates in absence 
of inhibitors were used as controls. Fluorescence in controls was 
arbitrarily set to 100 %. b Doxorubicin drug uptake profile in presence 
of CsA, Ko143 or MK571, * and ** denote P < 0.05 and P < 0.01 in 
comparison to C-Matrigel
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slightly lower than IMR90 iPSCs maintained in mTeSR. 
Such decreased drug efflux pump activity was also 
observed in the net uptake of doxorubicin (Fig. 5b), espe-
cially in cells differentiated on C-Matrigel. In conclusion, 
our data suggest that the nature of the medium used in 
maintenance of pluripotent stem cells has little impact 
on the differentiation process. However, the replacement 
of Matrigel by a defined ECM has a detrimental effect on 
BMEC differentiation.
Discussion
In the last few years, in  vitro models based on patient-
derived iPSCs have gained a sizable momentum in mod-
eling neurodegenerative disorders and certain types of 
epilepsies [22–25]. More recently, the publication of stem 
cell-based models of the human BBB brought a com-
plementary approach to other in  vitro models based on 
human primary cultures or on the hCMEC/D3 immor-
talized cell line [7–9, 11, 26–29]. Such patient-specific 
and disease-specific sources of cells may provide a valu-
able tool in modeling the impact of genetic disorders at 
the BBB and lead to a better understanding of how such 
disorders may result in the dysfunction of one or several 
components of the neurovascular unit (e.g. astrocytes, 
neurons, BMECs).
In their previous studies, Shusta and colleagues have 
established the method and demonstrated the ability 
to obtain BMECs from both embryonic and iPS stem 
cell lines with variable outcomes [7, 8, 11]. They used 
GFR-Matrigel and mTeSR as a foundation for the dif-
ferentiation. In this study, we investigated the impact 
of GFR-Matrigel from different sources and xeno-free 
culturing conditions (E-8 medium and Vitronectin) on 
BMEC differentiation using IMR90-c4, a human iPSC 
line [13]. In particular, the main driving force for our 
study was primed by the discontinuation of B-Matrigel 
production and its replacement by C-Matrigel.
Although the composition of GFR-Matrigel suggests a 
reduction in ECM-bound growth factors, a recent com-
parative proteomic study conducted by Hughes and col-
leagues between conventional and GFR-Matrigel has 
highlighted notable differences in their chemical com-
position [15]. Interestingly, the authors identified over 
400 peptides that were exclusively found inside the 
GFR-Matrigel and they also found signatures of proteins 
found naturally in cytoplasmic or nuclear compartments. 
Based on this study and our data, we can speculate that 
Matrigel composition may make an important contri-
bution to BMEC differentiation. We speculate that cell-
ECM interactions with integrins maybe an important 
driving force in this differentiation process, as we were 
not able to obtain any satisfactory differentiation when 
cells were grown on vitronectin-N. However, we cannot 
exclude the presence of non-ECM factors (e.g. growth 
factors) retained by the GFR-Matrigel that may influence 
such differentiation.
An interesting feature observed in our study was the 
notable decrease in barrier tightness when cells were 
grown on C-Matrigel. On this ECM, differentiating 
iPSC colonies failed to form neural tracts as observed 
by Shusta and colleagues [7, 8, 11]. Indeed, IMR90 dif-
ferentiating colonies on this substrate showed a macro-
scopical profile similar to the low-density (10 × 103 cells/
cm2) group described by Wilson et al. [11], although we 
initiated our differentiation at a much higher cell density 
(100  ×  103  cells/cm2). Barrier properties from BMEC 
monolayers differentiated in C-Matrigel shared similar 
values to BMECs purified from the low-density group, as 
marked by low TEER values (~300 Ω cm2). Notably such 
values coincide with those reported in the seminal study 
by Lippmann et  al. [8], in which BMEC differentiation 
was performed in absence of retinoic acid (RA). RA has 
been documented as a barrier inducer in hCMEC/D3 cell 
monolayers [30], yet the induction range was much more 
modest compared to IMR90-derived BMECs. We specu-
late that in our model, neuron progenitors described in 
such neural tracts might be secreting RA-induced factors 
resulting in the barrier tightening.
Finally, we observed significant differences between 
matrices in terms of undifferentiated stem cell dou-
bling time thus suggesting differences in growth factors 
intrinsic to GFR-Matrigel sources. GFR-Matrigel dif-
fers from regular Matrigel by an additional treatment 
with ammonium sulfate. Such treatment results in the 
reduction of growth factors bound to the extracellular 
matrix components contained within the Matrigel [31]. 
Thus, we speculate that one source of variability may 
originate from this essential step in the manufactur-
ing of the GFR-Matrigel. In this study, among the three 
different manufacturers providing stem cell qualified 
Matrigel, only one manufacturer (Trevigen) provided 
Matrigel that enabled IMR90-derived BMEC monocul-
tures to have barrier properties similar to the existing 
literature.
Conclusion
This study confirms the ability to differentiate iPSC-
derived BMECs from the IMR90-c4 cells as previously 
reported. Whereas the effect of stem cell maintenance 
medium has little impact on BMEC differentiation, 
variations in the production and manufacturing of 
GFR-Matrigel raised important issues that should fos-
ter further research. A transition from empirically-for-
mulated ECMs into a highly-defined synthetic scaffold 
would ensure consistent BMEC differentiation using a 
xeno-free, growth factor-independent medium.
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